WO2003093290A8 - Nucleoside derivatives for treating hepatitis c virus infection - Google Patents
Nucleoside derivatives for treating hepatitis c virus infectionInfo
- Publication number
- WO2003093290A8 WO2003093290A8 PCT/US2003/014237 US0314237W WO03093290A8 WO 2003093290 A8 WO2003093290 A8 WO 2003093290A8 US 0314237 W US0314237 W US 0314237W WO 03093290 A8 WO03093290 A8 WO 03093290A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus infection
- treating hepatitis
- nucleoside derivatives
- nucleoside
- hepatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/22—Pteridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2004-7017682A KR20050006221A (en) | 2002-05-06 | 2003-05-06 | Nucleoside derivatives for treating hepatitis c virus infection |
BR0309581-9A BR0309581A (en) | 2002-05-06 | 2003-05-06 | Nucleoside derivatives for treatment of hepatitis c virus infection |
NZ536123A NZ536123A (en) | 2002-05-06 | 2003-05-06 | Nucleoside derivatives for treating hepatitis C virus infection |
EP03747674A EP1501850A2 (en) | 2002-05-06 | 2003-05-06 | Nucleoside derivatives for treating hepatitis c virus infection |
JP2004501429A JP2005530759A (en) | 2002-05-06 | 2003-05-06 | Nucleoside derivatives for treating hepatitis C virus infection |
AU2003232071A AU2003232071A1 (en) | 2002-05-06 | 2003-05-06 | Nucleoside derivatives for treating hepatitis c virus infection |
MXPA04010983A MXPA04010983A (en) | 2002-05-06 | 2003-05-06 | Nucleoside derivatives for treating hepatitis c virus infection. |
CA002484921A CA2484921A1 (en) | 2002-05-06 | 2003-05-06 | Nucleoside derivatives for treating hepatitis c virus infection |
TW092128453A TW200423945A (en) | 2003-05-06 | 2003-10-14 | Nucleoside derivatives for treating hepatitis c virus infection |
IL16472904A IL164729A0 (en) | 2002-05-06 | 2004-10-20 | Nucleoside derivatives for treating hepatitis c virus infection |
NO20045247A NO20045247L (en) | 2002-05-06 | 2004-11-30 | Nucleoside derivatives for the treatment of hepatitis C virus infection |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37862402P | 2002-05-06 | 2002-05-06 | |
US60/378,624 | 2002-05-06 | ||
US39287102P | 2002-06-28 | 2002-06-28 | |
US60/392,871 | 2002-06-28 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003093290A2 WO2003093290A2 (en) | 2003-11-13 |
WO2003093290A3 WO2003093290A3 (en) | 2004-03-18 |
WO2003093290A8 true WO2003093290A8 (en) | 2005-05-19 |
Family
ID=31997164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/014237 WO2003093290A2 (en) | 2002-05-06 | 2003-05-06 | Nucleoside derivatives for treating hepatitis c virus infection |
Country Status (14)
Country | Link |
---|---|
US (1) | US20040063658A1 (en) |
EP (1) | EP1501850A2 (en) |
JP (1) | JP2005530759A (en) |
KR (1) | KR20050006221A (en) |
CN (1) | CN1653077A (en) |
AU (1) | AU2003232071A1 (en) |
BR (1) | BR0309581A (en) |
CA (1) | CA2484921A1 (en) |
IL (1) | IL164729A0 (en) |
MX (1) | MXPA04010983A (en) |
NO (1) | NO20045247L (en) |
NZ (1) | NZ536123A (en) |
RU (1) | RU2004135392A (en) |
WO (1) | WO2003093290A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9186369B2 (en) | 2003-07-25 | 2015-11-17 | Idenix Pharmaceuticals, Llc | Purine nucleoside analogues for treating flaviviridae including hepatitis C |
Families Citing this family (199)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
EP1284741B1 (en) | 2000-04-13 | 2008-11-19 | Pharmasset, Inc. | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CN101099745A (en) * | 2000-05-26 | 2008-01-09 | 艾登尼科斯(开曼)有限公司 | Methods and compositions for treating flaviviruses and pestiviruses |
WO2002059083A2 (en) * | 2000-10-23 | 2002-08-01 | Smithkline Beecham Corporation | Novel compounds |
US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
JP3914156B2 (en) | 2001-01-22 | 2007-05-16 | メルク エンド カムパニー インコーポレーテッド | Nucleoside derivatives as RNA-dependent RNA viral polymerase inhibitors |
AU2002330154A1 (en) * | 2001-09-28 | 2003-04-07 | Centre National De La Recherche Scientifique | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
US7321033B2 (en) * | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
US7217815B2 (en) * | 2002-01-17 | 2007-05-15 | Valeant Pharmaceuticals North America | 2-beta -modified-6-substituted adenosine analogs and their use as antiviral agents |
ATE370952T1 (en) * | 2002-04-19 | 2007-09-15 | Smithkline Beecham Corp | NEW CONNECTIONS |
WO2004000858A2 (en) * | 2002-06-21 | 2003-12-31 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AU2003269892A1 (en) * | 2002-06-27 | 2004-01-19 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
CN101172993A (en) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
RS113904A (en) * | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
PL374831A1 (en) * | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections |
AU2003269902A1 (en) * | 2002-07-16 | 2004-02-02 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AU2003256619A1 (en) | 2002-07-24 | 2004-02-09 | Isis Pharmaceuticals, Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
EP1545545A4 (en) | 2002-08-01 | 2008-09-03 | Pharmasset Inc | COMPOUNDS WITH THE BICYCLO 4.2.1 NONANE SYSTEM FOR THE TREATMENT OF i FLAVIVIRIDAE /i INFECTIONS |
KR20050059199A (en) * | 2002-09-30 | 2005-06-17 | 제네랩스 테크놀로지스, 인코포레이티드 | Nucleoside derivatives for treating hepatitis c virus infection |
HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
GB0228545D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Novel compounds |
US7598373B2 (en) * | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
BR0316868A (en) * | 2002-12-23 | 2005-10-25 | Idenix Cayman Ltd | Process for the Production of Nucleoside-3 'Prodrugs |
US7799908B2 (en) * | 2003-01-15 | 2010-09-21 | Valeant Pharmaceuticals North America | Synthesis and use of 2′-substituted-N6 -modified nucleosides |
US7407962B2 (en) | 2003-02-07 | 2008-08-05 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors or protein kinases |
WO2004098590A1 (en) * | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | 4-bromo-5- (2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-(aminocarbonyl) eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases |
TW200509910A (en) * | 2003-05-02 | 2005-03-16 | Elan Pharm Inc | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists |
ATE435649T1 (en) * | 2003-05-02 | 2009-07-15 | Elan Pharm Inc | 4-BROMINE-5-(2-CHLORINE-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES |
US7576068B2 (en) | 2003-09-05 | 2009-08-18 | Anadys Pharmaceuticals, Inc. | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus |
US20050182252A1 (en) * | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
ES2431314T3 (en) | 2004-02-20 | 2013-11-26 | Boehringer Ingelheim International Gmbh | Viral Polymerase Inhibitors |
SG136123A1 (en) | 2004-03-04 | 2007-10-29 | Leuven K U Res & Dev | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production |
AU2005254057B2 (en) * | 2004-06-15 | 2011-02-17 | Isis Pharmaceuticals, Inc. | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase |
EP1912643A2 (en) * | 2004-06-23 | 2008-04-23 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
WO2006012078A2 (en) | 2004-06-24 | 2006-02-02 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
EP1804811A4 (en) * | 2004-09-24 | 2011-04-27 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus |
AU2005302448B2 (en) | 2004-10-29 | 2012-07-19 | Biocryst Pharmaceuticals, Inc. | Therapeutic furopyrimidines and thienopyrimidines |
PT2561872E (en) | 2004-12-17 | 2014-12-18 | Anadys Pharmaceuticals Inc | 3, 5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof |
JP5002851B2 (en) * | 2005-01-20 | 2012-08-15 | 独立行政法人理化学研究所 | Imidazopyridine derivatives |
CA2600359A1 (en) * | 2005-03-09 | 2006-09-09 | Idenix (Cayman) Limited | Nucleosides with non-natural bases as anti-viral agents |
KR20080002865A (en) * | 2005-03-25 | 2008-01-04 | 글락소 그룹 리미티드 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives |
TW200724142A (en) * | 2005-03-25 | 2007-07-01 | Glaxo Group Ltd | Novel compounds |
US7423042B2 (en) | 2005-03-25 | 2008-09-09 | Glaxo Group Limited | Compounds |
MY145281A (en) | 2005-03-25 | 2012-01-13 | Glaxo Group Ltd | Novel compounds |
US7514410B2 (en) | 2005-03-29 | 2009-04-07 | Biocryst Pharmaceuticals, Inc. | Hepatitis C therapies |
US7879797B2 (en) * | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US7569600B2 (en) | 2005-05-13 | 2009-08-04 | Virochem Pharma Inc. | Compounds and methods for the treatment of prevention of Flavivirus infections |
AR057456A1 (en) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | HCV PROTEASA NS3 INHIBITORS |
KR20080036598A (en) | 2005-08-01 | 2008-04-28 | 머크 앤드 캄파니 인코포레이티드 | Macrocyclic peptides as hcv ns3 protease inhibitors |
CA2618560A1 (en) * | 2005-08-09 | 2007-02-22 | Merck & Co., Inc. | Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection |
KR20140105621A (en) | 2005-10-07 | 2014-09-01 | 엑셀리시스, 인코포레이티드 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
CN102746298A (en) | 2005-10-07 | 2012-10-24 | 埃克塞里艾克西斯公司 | Pyridopyrimidinone inhibitors of Pl3K[alpha] |
AU2006318260B2 (en) | 2005-11-21 | 2012-05-17 | Anadys Pharmaceuticals, Inc. | Process for the preparation of 5-amino-3H- thiazolo [4 , 5 -d] pyrimidin- 2 -one |
WO2007064795A2 (en) * | 2005-11-30 | 2007-06-07 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
CA2634749C (en) * | 2005-12-23 | 2014-08-19 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
AU2007229463A1 (en) * | 2006-03-23 | 2007-10-04 | Inotek New Zealand Limited | Purine compounds and methods of use thereof |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US7709448B2 (en) * | 2006-06-22 | 2010-05-04 | Anadys Pharmaceuticals, Inc. | Prodrugs of 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione |
GB0612423D0 (en) * | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
EP2040712B1 (en) | 2006-07-18 | 2011-03-02 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines |
EP2074122B9 (en) | 2006-09-15 | 2013-09-11 | Pfizer Products Inc. | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
JP5513119B2 (en) * | 2006-10-19 | 2014-06-04 | シグナル ファーマシューティカルズ,エルエルシー | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
JP5345941B2 (en) | 2006-10-24 | 2013-11-20 | メルク・シャープ・アンド・ドーム・コーポレーション | HCV NS3 protease inhibitor |
EP2076278B1 (en) | 2006-10-24 | 2015-05-06 | Merck Sharp & Dohme Corp. | Macrocyclic HCV NS3 protease inhibitors |
WO2008051475A2 (en) * | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US8377874B2 (en) * | 2006-10-27 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
BRPI0718161A2 (en) * | 2006-10-27 | 2013-11-26 | Merck & Co Inc | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF THE COMPOUND. |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2008075103A1 (en) * | 2006-12-20 | 2008-06-26 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
GB0625349D0 (en) * | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US20080261913A1 (en) * | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
US8071568B2 (en) | 2007-01-05 | 2011-12-06 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
TW200838550A (en) * | 2007-02-09 | 2008-10-01 | Novartis Ag | Organic compounds |
GB0709791D0 (en) * | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
US8183249B2 (en) * | 2007-07-12 | 2012-05-22 | University Of South Florida | Inhibitors of AKT/PKB with anti-tumor activity |
EP2178886A1 (en) | 2007-07-17 | 2010-04-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
CA2699891C (en) * | 2007-07-19 | 2013-10-22 | Nigel Liverton | Macrocyclic compounds as antiviral agents |
CA2722177C (en) * | 2008-04-23 | 2016-08-16 | Gilead Sciences, Inc. | 1'-substituted carba-nucleoside analogs for antiviral treatment |
US8461107B2 (en) | 2008-04-28 | 2013-06-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
CN102177172A (en) * | 2008-07-02 | 2011-09-07 | 埃迪尼克斯医药公司 | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2010002877A2 (en) * | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
DK2540350T3 (en) | 2008-07-22 | 2014-08-04 | Merck Sharp & Dohme | COMBINATIONS OF A MACROCYCLIC QUINOXAL COMPOUND, WHICH IS ANHCV-NS3 PROTEASE INHIBITOR WITH OTHER HCV AGENTS |
UA103195C2 (en) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
GB0815968D0 (en) * | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
WO2010039740A1 (en) | 2008-09-30 | 2010-04-08 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
WO2010101951A1 (en) | 2009-03-02 | 2010-09-10 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
BRPI1009324A2 (en) * | 2009-03-20 | 2015-11-24 | Alios Biopharma Inc | and / or pharmaceutically acceptable compounds thereof, pharmaceutical composition and their uses |
EP2414044A1 (en) | 2009-03-31 | 2012-02-08 | ArQule, Inc. | Substituted indolo-piperidine compounds |
MX2011011160A (en) * | 2009-04-22 | 2012-01-27 | Acad Of Science Czech Republic | Novel 7-deazapurine nucleosides for therapeutic uses. |
TW201602113A (en) | 2009-06-29 | 2016-01-16 | 英塞特公司 | Pyrimidinones as PI3K inhibitors |
US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
US20110027229A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients |
MX2012003126A (en) | 2009-09-21 | 2012-06-19 | Gilead Sciences Inc | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs. |
CN102686599B (en) * | 2009-09-29 | 2016-10-05 | 杨森产品有限公司 | The Phosphoramidate derivatives of nucleosides |
CN106117213B (en) | 2009-10-26 | 2022-03-18 | 西格诺药品有限公司 | Heteroaryl compounds and methods for their synthesis and purification |
WO2011075643A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
TW201130842A (en) * | 2009-12-18 | 2011-09-16 | Incyte Corp | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
EP2528930B1 (en) * | 2010-01-28 | 2013-10-30 | F.Hoffmann-La Roche Ag | 4'-azido-nucleosides as anti-hcv compounds |
AR080151A1 (en) | 2010-02-09 | 2012-03-14 | Exelixis Inc | METHODS TO TREAT CANCER USING PI 3K PYRIDOPIRIMIDINONE INHIBITORS AND MTOR IN COMBINATION WITH AUTOPHAGIA INHIBITORS |
JP2013523765A (en) | 2010-04-01 | 2013-06-17 | イデニク プハルマセウティカルス,インコーポレイテッド | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2011123621A2 (en) | 2010-04-01 | 2011-10-06 | Alnylam Pharmaceuticals Inc. | 2' and 5' modified monomers and oligonucleotides |
JP5816678B2 (en) | 2010-04-14 | 2015-11-18 | インサイト・コーポレイションIncyte Corporation | Condensed derivatives as PI3Kδ inhibitors |
WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
JP5937073B2 (en) | 2010-07-19 | 2016-06-22 | ギリード・サイエンシズ・インコーポレーテッド | Process for the preparation of diastereomeric pure phosphoramidate prodrugs |
SI2595980T1 (en) | 2010-07-22 | 2014-11-28 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
JP6012605B2 (en) | 2010-09-22 | 2016-10-25 | アリオス バイオファーマ インク. | Substituted nucleotide analogs |
US20120295911A1 (en) | 2010-11-29 | 2012-11-22 | Galleon Pharmaceuticals, Inc. | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases |
AU2011336764B2 (en) | 2010-11-29 | 2017-02-23 | Galleon Pharmaceuticals, Inc. | Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases |
US9096600B2 (en) | 2010-12-20 | 2015-08-04 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
EP2658857B1 (en) * | 2010-12-29 | 2016-11-02 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
AU2012234259A1 (en) * | 2011-03-31 | 2013-10-03 | Libera-Korner, Jeanette | Perfluorinated compounds for the non-viral transfer of nucleic acids |
CN103842369A (en) | 2011-03-31 | 2014-06-04 | 埃迪尼克斯医药公司 | Compounds and pharmaceutical compositions for the treatment of viral infections |
EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US9150603B2 (en) | 2011-04-13 | 2015-10-06 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases |
BR112013026345A2 (en) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | compound, pharmaceutical composition, use of a compound, and method for treating an hcv infected patient |
US9416154B2 (en) | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2013009737A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
US10112946B2 (en) | 2011-07-22 | 2018-10-30 | Glaxosmithkline Llc | Composition |
TWI765515B (en) | 2011-09-02 | 2022-05-21 | 美商英塞特控股公司 | Heterocyclylamines as pi3k inhibitors |
ES2751921T3 (en) | 2011-10-19 | 2020-04-02 | Signal Pharm Llc | Cancer treatment with TOR kinase inhibitors |
WO2013074386A2 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
CA3125862A1 (en) | 2011-12-02 | 2013-06-06 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
AU2012358804B2 (en) | 2011-12-22 | 2018-04-19 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
US9375443B2 (en) | 2012-02-24 | 2016-06-28 | Signal Pharmaceuticals, Llc | Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib |
NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
EP2854813B1 (en) * | 2012-05-31 | 2018-07-25 | Bio-lab Ltd. | Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them |
AR092198A1 (en) | 2012-08-24 | 2015-04-08 | Glaxosmithkline Llc | DERIVATIVES OF PIRAZOLOPIRIMIDINAS |
US9556216B2 (en) | 2012-08-31 | 2017-01-31 | Novartis Ag | 2′-Ethynyl nucleoside derivatives for treatment of viral infections |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
MX2015005500A (en) * | 2012-10-29 | 2016-02-09 | Cocrystal Pharma Inc | Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer. |
WO2014074883A1 (en) * | 2012-11-08 | 2014-05-15 | Lyndor Biosciences L.L.C. | Novel synthesis of ld101 |
ME02867B (en) * | 2012-11-20 | 2018-04-20 | Glaxosmithkline Llc | Novel compounds |
WO2014081643A1 (en) * | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
AU2013348217B2 (en) | 2012-11-20 | 2016-10-06 | Glaxosmithkline Llc | Novel compounds |
AR094494A1 (en) | 2013-01-16 | 2015-08-05 | Signal Pharm Llc | REPLACED PIRROLOPIRIMIDINS, THEIR COMPOSITIONS, AND THEIR TREATMENT METHODS |
WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
US9447132B2 (en) | 2013-04-12 | 2016-09-20 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of HCV |
ES2744198T3 (en) | 2013-04-17 | 2020-02-24 | Signal Pharm Llc | Pharmaceutical formulations, processes, solid forms and methods of use related to 1-ethyl-7- (2-methyl-6- (1H-1,2,4-triazol-3-yl) pyridin-3-yl) -3, 4 dihydropyrazine [2,3-b] pyrazin-2 (1H) -one |
UA119538C2 (en) | 2013-04-17 | 2019-07-10 | Сігнал Фармасьютікалз, Елелсі | Treatment of cancer with dihydropyrazino-pyrazines |
TWI674897B (en) | 2013-04-17 | 2019-10-21 | 美商標誌製藥公司 | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
CA2909625C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
KR102221029B1 (en) | 2013-04-17 | 2021-02-26 | 시그날 파마소티칼 엘엘씨 | Treatment of cancer with dihydropyrazino-pyrazines |
MX2015014599A (en) | 2013-04-17 | 2016-03-03 | Signal Pharm Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer. |
EP2986319A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
NZ629486A (en) | 2013-05-29 | 2017-11-24 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
LT3043803T (en) | 2013-09-11 | 2022-08-10 | Emory University | Nucleotide and nucleoside compositions and their uses |
CN114404427A (en) | 2014-02-13 | 2022-04-29 | 配体药物公司 | Prodrug compound and use thereof |
EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
JP2017514806A (en) | 2014-04-16 | 2017-06-08 | シグナル ファーマシューティカルズ,エルエルシー | Methods of treating cancer using TOR kinase inhibitor combination therapy |
WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
CN106687118A (en) | 2014-07-02 | 2017-05-17 | 配体药物公司 | Prodrug compounds and uses thereof |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
KR20170024120A (en) | 2014-07-14 | 2017-03-06 | 시그날 파마소티칼 엘엘씨 | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
TWI740546B (en) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | Methods for the preparation of ribosides |
HUE060953T2 (en) | 2015-02-27 | 2023-04-28 | Incyte Holdings Corp | Processes for the preparation of a pi3k inhibitor |
EP3265102A4 (en) * | 2015-03-06 | 2018-12-05 | ATEA Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
CN107820499B (en) | 2015-04-28 | 2022-11-11 | 鲁汶大学研究与开发部 | Antiviral compounds, process for their preparation, and their use for the treatment of viral infections |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2017049060A1 (en) | 2015-09-16 | 2017-03-23 | Gilead Sciences, Inc. | Methods for treating arenaviridae and coronaviridae virus infections |
US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
KR20190043602A (en) | 2016-09-07 | 2019-04-26 | 아테아 파마슈티컬즈, 인크. | 2'-substituted-N6-substituted purine nucleotides for the treatment of RNA viruses |
CA3045876A1 (en) | 2016-11-11 | 2018-05-17 | The Queen's University Of Belfast | Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
CN110234238B (en) | 2016-11-29 | 2023-03-28 | 爱荷华大学研究基金会 | Use of NAD precursors for improving maternal and/or offspring health |
US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
SG11201906163TA (en) | 2017-02-01 | 2019-08-27 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
EP4331677A2 (en) | 2017-03-14 | 2024-03-06 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
EP3618929B1 (en) | 2017-05-01 | 2022-12-07 | Gilead Sciences, Inc. | A crystalline form of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
BR112019027402A2 (en) | 2017-06-22 | 2020-07-07 | Celgene Corporation | treatment of hepatocellular carcinoma characterized by infection with the hepatitis b virus |
US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
TWI802635B (en) * | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
CN108484705B (en) * | 2018-01-25 | 2020-09-01 | 中国医学科学院医药生物技术研究所 | Cinefungin analogue and preparation method thereof |
CN112351799A (en) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | Treatment of HCV infected patients with cirrhosis |
CN109776638A (en) * | 2019-04-01 | 2019-05-21 | 大连大学 | A kind of 5-Br-3 ', 5 '-O- diacetyls -2 '-BrdU synthetic method |
CN109897081A (en) * | 2019-04-01 | 2019-06-18 | 大连大学 | A kind of 5-Br-2 ', 3 ', 5 '-O- triacetyl uridine synthetic methods |
TW202313067A (en) | 2020-01-27 | 2023-04-01 | 美商基利科學股份有限公司 | Methods for treating sars cov-2 infections |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
CA3169340A1 (en) | 2020-03-12 | 2021-09-16 | Pavel R. Badalov | Methods of preparing 1'-cyano nucleosides |
KR20220164784A (en) | 2020-04-06 | 2022-12-13 | 길리애드 사이언시즈, 인코포레이티드 | Inhalation Formulations of 1′-Cyano Substituted Carbanucleoside Analogues |
CN111995649A (en) * | 2020-04-09 | 2020-11-27 | 瀚海新拓(杭州)生物医药有限公司 | Pteridinone nucleotide analogue and pharmaceutical composition, preparation method and medical application thereof |
US20210393653A1 (en) | 2020-05-29 | 2021-12-23 | Gilead Sciences, Inc. | Remdesivir treatment methods |
BR112022026321A2 (en) | 2020-06-24 | 2023-01-17 | Gilead Sciences Inc | 1'-CYAN NUCLEOSIDE ANALOGS AND USES THEREOF |
JP2023540225A (en) | 2020-08-27 | 2023-09-22 | ギリアード サイエンシーズ, インコーポレイテッド | Compounds and methods for the treatment of viral infections |
CA3194161A1 (en) * | 2020-10-02 | 2022-04-07 | David M. Evans | Nucleoside containing sirnas for treating viral diseases |
CN112851719A (en) * | 2021-03-10 | 2021-05-28 | 康化(上海)新药研发有限公司 | Method for synthesizing giardiamycin |
WO2023022216A1 (en) | 2021-08-20 | 2023-02-23 | 塩野義製薬株式会社 | Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action |
WO2023102242A2 (en) * | 2021-12-03 | 2023-06-08 | Quralis Corporation | Splice switcher antisense oligonucleotides with modified backbone chemistries |
WO2023167944A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1521076A (en) * | 1966-05-02 | 1968-04-12 | Merck & Co Inc | Substituted purine nucleosides |
US3480613A (en) * | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
US4140851A (en) * | 1977-11-21 | 1979-02-20 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides |
US6211158B1 (en) * | 1987-04-10 | 2001-04-03 | Roche Diagnostics Gmbh | Desazapurine-nucleotide derivatives, processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof for nucleic acid sequencing and as antiviral agents |
US5681941A (en) * | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
GB9225427D0 (en) * | 1992-12-04 | 1993-01-27 | Ribonetics Gmbh | Oligonucleotides with rna cleavage activity |
US6004939A (en) * | 1995-07-06 | 1999-12-21 | Ctrc Research Foundation Board Of Regents | Methods for modulation and inhibition of telomerase |
WO1997002279A1 (en) * | 1995-07-06 | 1997-01-23 | Ctrc Research Foundation | Methods and compositions for modulation and inhibition of telomerase |
US6831069B2 (en) * | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CN101099745A (en) * | 2000-05-26 | 2008-01-09 | 艾登尼科斯(开曼)有限公司 | Methods and compositions for treating flaviviruses and pestiviruses |
JP3914156B2 (en) * | 2001-01-22 | 2007-05-16 | メルク エンド カムパニー インコーポレーテッド | Nucleoside derivatives as RNA-dependent RNA viral polymerase inhibitors |
WO2003055896A2 (en) * | 2001-12-21 | 2003-07-10 | Micrologix Biotech Inc. | Anti-viral 7-deaza l-nucleosides |
AU2003237249A1 (en) * | 2002-05-24 | 2003-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
-
2003
- 2003-05-06 US US10/431,631 patent/US20040063658A1/en not_active Abandoned
- 2003-05-06 EP EP03747674A patent/EP1501850A2/en not_active Withdrawn
- 2003-05-06 NZ NZ536123A patent/NZ536123A/en unknown
- 2003-05-06 KR KR10-2004-7017682A patent/KR20050006221A/en not_active Application Discontinuation
- 2003-05-06 CN CNA038102390A patent/CN1653077A/en active Pending
- 2003-05-06 WO PCT/US2003/014237 patent/WO2003093290A2/en active Search and Examination
- 2003-05-06 CA CA002484921A patent/CA2484921A1/en not_active Abandoned
- 2003-05-06 JP JP2004501429A patent/JP2005530759A/en not_active Withdrawn
- 2003-05-06 MX MXPA04010983A patent/MXPA04010983A/en unknown
- 2003-05-06 RU RU2004135392/04A patent/RU2004135392A/en not_active Application Discontinuation
- 2003-05-06 BR BR0309581-9A patent/BR0309581A/en not_active IP Right Cessation
- 2003-05-06 AU AU2003232071A patent/AU2003232071A1/en not_active Abandoned
-
2004
- 2004-10-20 IL IL16472904A patent/IL164729A0/en unknown
- 2004-11-30 NO NO20045247A patent/NO20045247L/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9186369B2 (en) | 2003-07-25 | 2015-11-17 | Idenix Pharmaceuticals, Llc | Purine nucleoside analogues for treating flaviviridae including hepatitis C |
Also Published As
Publication number | Publication date |
---|---|
EP1501850A2 (en) | 2005-02-02 |
NO20045247L (en) | 2004-11-30 |
BR0309581A (en) | 2005-03-29 |
US20040063658A1 (en) | 2004-04-01 |
RU2004135392A (en) | 2005-06-27 |
CA2484921A1 (en) | 2003-11-13 |
WO2003093290A3 (en) | 2004-03-18 |
MXPA04010983A (en) | 2005-02-14 |
AU2003232071A1 (en) | 2003-11-17 |
WO2003093290A2 (en) | 2003-11-13 |
KR20050006221A (en) | 2005-01-15 |
IL164729A0 (en) | 2005-12-18 |
NZ536123A (en) | 2006-09-29 |
CN1653077A (en) | 2005-08-10 |
JP2005530759A (en) | 2005-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003093290A8 (en) | Nucleoside derivatives for treating hepatitis c virus infection | |
WO2004028481A3 (en) | Nucleoside derivatives for treating hepatitis c virus infection | |
WO2006075993A3 (en) | Nucleoside derivatives for treating hepatitis c virus infection | |
AU2002364730A1 (en) | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | |
TW200517381A (en) | Bicyclic heteroaryl derivatives | |
WO2006138744A3 (en) | Heteroaryl derivatives for treating viruses | |
WO2004011478A3 (en) | Anti-viral 7-deaza d-nucleosides and uses thereof | |
AU2003249977A1 (en) | Imidazole compounds for the treatment of hepatitis c virus infections | |
PL378354A1 (en) | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections | |
BRPI0415883A (en) | nucleoside compounds and compositions for the treatment of viral infections | |
WO2007084413A3 (en) | Methods for treating hepatitis c | |
WO2004002940A8 (en) | Inhibitors of hcv ns5b polymerase | |
WO2001077091A3 (en) | Ns5b hcv polymerase inhibitors | |
WO2007001406A3 (en) | Aryl-containing macrocyclic compounds | |
WO2007041632A3 (en) | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection | |
AU2002346686A1 (en) | Compositions and method for treating hepatitis virus infection | |
NO20056100L (en) | Nitrogen-containing heteroaryl derivatives | |
AU2003294757A1 (en) | Formulations useful against hepatitis c virus infections | |
WO2004052905A3 (en) | Antiviral nucleoside derivatives | |
AU2003237088A1 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
AU2003258176A1 (en) | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | |
AU2003302275A1 (en) | Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses | |
AU2003256678A1 (en) | Method and composition for treating and preventing hepatitis c infection | |
WO2004064784A3 (en) | Composition and method for preventing or treating a virus infection | |
AU2003258177A1 (en) | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003232071 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 536123 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/08588 Country of ref document: ZA Ref document number: 200408588 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047017682 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/010983 Country of ref document: MX Ref document number: 2484921 Country of ref document: CA Ref document number: 20038102390 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004501429 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003747674 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004135392 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047017682 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003747674 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 46/2003 UNDER (84) ADD "HU" (EP) |